Skip to main content
. 2022 Nov 11;5(11):e2241731. doi: 10.1001/jamanetworkopen.2022.41731

Figure 2. Bioverified Continuous Abstinence Rates for Each Run-in Group and Each Group × Sex Condition at End of Treatment.

Figure 2.

Bioverification used continine levels to verify rates at end of treatment (primary outcome).